Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Sees Large Drop in Short Interest

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the target of a large drop in short interest in August. As of August 14th, there was short interest totaling 148,118 shares, a drop of 38.3% from the July 30th total of 240,225 shares. Based on an average daily trading volume, of 159,888 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.0% of the shares of the stock are short sold.

Daiichi Sankyo Trading Down 2.3%

Shares of DSNKY stock opened at $17.95 on Tuesday. The company has a market cap of $33.44 billion, a PE ratio of 20.87, a price-to-earnings-growth ratio of 2.52 and a beta of -0.18. Daiichi Sankyo has a 1 year low of $14.98 and a 1 year high of $27.50. The stock’s 50 day simple moving average is $17.08 and its two-hundred day simple moving average is $17.35. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.42 and a quick ratio of 1.64.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings results on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Daiichi Sankyo had a return on equity of 14.22% and a net margin of 10.92%.The company had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. Research analysts predict that Daiichi Sankyo will post 0.97 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on DSNKY. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Monday, August 3rd. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce”.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.